A Single-Blind, Randomized, Placebo Controlled Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula C Sublingual +Drops in People with Post-Acute Coronavirus Disease 2019 Syndrome.

Young, Thomas P; Erickson, Joel S; Hattan, Shannon L; Guzy, Serge; Hershkowitz, Fabienne; Steward, Michael D

Young, Thomas P; Erickson, Joel S; Hattan, Shannon L; Guzy, Serge; Hershkowitz, Fabienne; Steward, Michael D.

Afiliação

Young TP; Joel S Erickson, MD+Thomas P Young, PhD, NP, Inc., Novato, California, USA.
Erickson JS; Joel S Erickson, MD+Thomas P Young, PhD, NP, Inc., Novato, California, USA.
Hattan SL; Joel S Erickson, MD+Thomas P Young, PhD, NP, Inc., Novato, California, USA.
Guzy S; ProPharma, Inc., Hillsborough, New Jersey, USA.
Hershkowitz F; ProPharma, Inc., Hillsborough, New Jersey, USA.
Steward MD; Endourage, LLC, Wheatridge, Colorado, USA.

Cannabis Cannabinoid Res ; 2022 Oct 14.

Article em En | MEDLINE | ID: mdl-36252151

Palavras-chave

CBD; COVID-19; PACS; cannabidiol; integrative medicine; long-hauler

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Cannabis Cannabinoid Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google